Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company that applies structure-based drug design and computational chemistry to the development of oral small molecule therapeutics. Its technical focus spans small molecule drug discovery and the formulation of orally administered medicines, with the aim of addressing limitations associated with biologic and peptide drugs. The company's pipeline comprises oral small molecule candidates targeting chronic diseases with high unmet medical needs.

The therapeutic areas covered by its work include metabolic disease, obesity, diabetes and cardiovascular disease. The company states an emphasis on medicines that are accessible and scalable for patients worldwide.

Structure Therapeutics completed its initial public offering in February 2023 and is listed on NASDAQ under the ticker GPCR. It operates from South San Francisco, California, and Shanghai, China, and describes its leadership as a team of experienced international drug innovators supported by global life sciences investors.